Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancer cells
Authors:
- J. A. MenendezJ. A. Menendez
- S. RoperoSRS. Ropero
- R. LupuRLR. Lupu
- R. ColomerRCR. Colomer
Open Access
- 1 November 2004
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 15 (11) , 1719-1721
Abstract
Research from several sources provides strong evidence that dietary or exogenously derived fatty acids (FAs) may play an important role in the etiology, evolution and/or progression of breast cancer [1]. However, the type of individual FAs in a diet, rather than the amount of total dietary fat, may be more important in breast cancer disease. In this regard, epidemiological, experimental and mechanistic data implicate ω-9 oleic acid (OA; 18:1n-9), the main FA of olive oil, α-linolenic acid (ALA; 18:3n-3), the ω-3 FA of vegetable oils, and eicosapentaneoic (EPA; 22:5n-3) and docosahexaenoic (DHA; 22:6n-3) FAs, the two main ω-3 FAs of fish oils, as inhibitors of the development and progression of human breast cancer, and ω-6 FAs such as linoleic acid (LA; 18:2n-6), the main FA of corn and sunflower oils, as stimulators of the disease. Moreover, one of the most interesting yet controversial dietary approaches has been the possible role of dietary FAs in treating breast cancer. However, little is know about the ultimate mechanisms underlying FA-regulated breast cancer risk and progression. Interestingly, we previously reported that exogenous supplementation with FAs such as γ-linolenic acid (GLA; 18:3n-6), an essential FA found in the plant-seed oils of evening primrose, blackcurrant and borage oils, synergically sensitizes cultured breast cancer cells to anti-mitotic drugs such as paclitaxel (Taxol™) [2], vinorelbine (Navelbine™) [3] and docetaxel (Taxotere™) [4]. Moreover, this GLA-induced sensitization was also synergic with the anti-estrogens tamoxifen and ICI 182,780 (Faslodex™) [5]. Since the human Her-2/neu (c-erbB-2) oncogene and its p185Her-2/neu orphan receptor oncoprotein, which are overexpressed in 25–30% of invasive breast cancers, have been associated with cytotoxic and endocrine therapy resistance [6], we recently envisioned that FA-induced breast cancer chemosensitization may involve regulation of Her-2/neu-dependent signaling.Keywords
This publication has 15 references indexed in Scilit:
- Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2Oncogene, 2004
- ω‐6 Polyunsaturated fatty acid γ‐linolenic acid (18:3n‐6) is a selective estrogen‐response modulator in human breast cancer cells: γ‐Linolenic acid antagonizes estrogen receptor‐dependent transcriptional activity, transcriptionally represses estrogen receptor expression and synergistically enhances tamoxifen and ICI 182,780 (Faslodex) efficacy in human breast cancer cellsInternational Journal of Cancer, 2004
- Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domainAnnals of Oncology, 2004
- Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast CancerClinical Chemistry, 2003
- Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatmentBritish Journal of Cancer, 2003
- Synergistic Interaction Between Vinorelbine and Gamma-Linolenic Acid in Breast Cancer CellsBreast Cancer Research and Treatment, 2002
- Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cellsEuropean Journal of Cancer, 2001
- Role of erbB2 in breast cancer chemosensitivityBioEssays, 2000
- Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiersCarcinogenesis, 1999
- Regulation of Cyclooxygenase-2 pathway by HER2 receptorOncogene, 1999